Last checked at 10 Nov 2014 07:00
10 November 2014
Revolymer plc
("Revolymer" or "the Company")
Notice of Settlement and Discontinuation of Patent Infringement Proceedings
In respect of the alleged patent infringement action brought by Fertin Pharma A/S and Gumlink A/S against the Company relating to the sale of its nicotine gum products in Canada (the "Action"), Revolymer is pleased to announce that the Action, and the counterclaim forming part of Revolymer's defence, has been settled and discontinued.
Ends
For further information please contact:
Revolymer plc | +44 (0) 1244 283 500 |
Kevin Matthews / Rob Cridland
| |
Panmure Gordon (UK) Limited | +44 (0) 20 7886 2500 |
Hugh Morgan / Adam James (Corporate Finance) Charles Leigh-Pemberton (Corporate Broking) | |
Citigate Dewe Rogerson | +44 (0)20 7282 2867 |
David Dible / Malcolm Robertson
|
About Revolymer
Revolymer is a technology company that designs, develops and formulates novel polymers to improve the performance of existing consumer products within the FMCG markets. Revolymer's strategy is to generate significant and growing revenue streams by licensing its unique and proprietary technologies to manufacturers and marketers within the global high value FMCG industry. Current applications for the Group's technologies are in the coatings & adhesives, household products and personal care markets (together "Consumer Specialties") and the confectionery chewing gum and medicated chewing gum (together "Gum") markets.
www.revolymer.com